CNTA News and Press, Centessa Pharmaceuticals plc From 08/23/23

BOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that preclinical data for ORX750, its first orexin ...

2023-08-17 11:58:40 ET Summary Centessa Pharmaceuticals takes a unique "asset-centric" approach in the biopharmaceutical industry, offering advantages such as reduced risk, improved efficiency, and greater potential for innovation. The company has a strong financial position with ...

2023-08-14 09:56:13 ET Centessa Pharmaceuticals press release ( NASDAQ: CNTA ): Q2 GAAP EPS of -$0.26. Cash, Cash Equivalents and Short-term Investments: $303.6 million as of June 30, 2023. For further details see: Centessa Pharmaceuticals GAAP EPS of -$0.26

Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia B Enrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody ® for the treatment of solid tumors IND-enabling activities advancing for ...

BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registration...

BOSTON and LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has gra...

2023-05-22 06:08:05 ET Summary Centessa Pharmaceuticals has a highly diverse pipeline. Its lead asset has produced some decent data in hemophilia. Cash runway is also decent. Centessa Pharmaceuticals ( CNTA ) develops medicines for hemophilia A, solid tumors, nar...

2023-05-12 07:27:47 ET Centessa Pharmaceuticals press release ( NASDAQ: CNTA ): Q1 GAAP EPS of -$0.53. Cash, Cash Equivalents and Short-term Investments: $346.2 million as of March 31, 2023, which the Company expects will fund operations into 2026, without drawing on ...

– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing ...

2023-03-30 08:51:14 ET Centessa Pharmaceuticals press release ( NASDAQ: CNTA ): Q4 GAAP EPS of -$0.45 misses by $0.01 . Cash and Cash Equivalents: $393.6 million as of December 31, 2022, which the Company expects will fund operations into 2026, without drawing on ...